Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis
Abstract
Background: It is increasingly recognized that gut microbiota play a pivotal role in the development of atherosclerotic cardiovascular disease. Previously, we have reported that the abundance of genus Bacteroides is lower in patients with coronary artery disease (CAD) than in patients without CAD with coronary risk factors or in healthy volunteers. However, it remains unclear which and how specific gut bacteria contribute to the progression of atherosclerosis. Methods: We recruited patients with CAD patients and controls without CAD with coronary risk factors. We then compared gut microbial composition using 16S ribosomal RNA gene sequencing in fecal samples to detect species with differential abundance between 2 groups. Subsequently, we used atherosclerosis-prone mice to study the mechanisms underlying the relationship between such species and atherosclerosis. Results: Human fecal 16S ribosomal RNA gene sequencing revealed a significantly lower abundance of Bacteroides vulgatus and Bacteroides dorei in patients with CAD. This significant differential abundance was confirmed by quantitative polymerase chain reaction. Gavage with live B. vulgatus and B. dorei attenuated atherosclerotic lesion formation in atherosclerosis-prone mice, markedly ameliorating endotoxemia followed by decreasing gut microbial lipopolysaccharide production, effectively suppressing proinflammatory immune responses. Furthermore, fecal lipopolysaccharide levels in patients with CAD were significantly higher and negatively correlated with the abundance of B. vulgatus and B. dorei . Conclusions: Our translational research findings identify a previously unknown link between specific gut bacteria and atherosclerosis. Treatment with live B. vulgatus and B. dorei may help prevent CAD. Clinical Trial Registration: URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018051 . Unique identifier: UMIN000015703.
AI snapshot
Written from the paper’s full text.
TL;DR
In patients with coronary artery disease (CAD), gut abundance of *Bacteroides vulgatus* and *Bacteroides dorei* was lower than in controls without CAD, and fecal lipopolysaccharide (LPS) levels were higher. In atherosclerosis-prone mice, oral gavage with live *B. vulgatus* and *B. dorei* reduced fecal and plasma LPS, dampened inflammation, and attenuated atherosclerotic plaque.
Key findings
- In 30 patients with CAD versus 30 age- and sex-matched controls without CAD but with coronary risk factors, 16S rRNA sequencing showed relative depletion of *B. vulgatus* and *B. dorei* in CAD; qPCR confirmed significantly decreased abundance of these species.
- Fecal LPS levels were significantly higher in patients with CAD than controls, and fecal LPS correlated negatively with *B. vulgatus*/*B. dorei* abundance in CAD (r=−0.541, P=0.002); genus *Bacteroides* showed a trend toward negative correlation (r=−0.227, P=0.0838).
- In apolipoprotein E-deficient mice, gavage with live *B. vulgatus* and *B. dorei* (2.5×10⁹ cfu/100 μL, 5 times/week) significantly reduced aortic root and en face atherosclerotic lesion size, macrophage and CD4⁺ T-cell accumulation, plasma LPS, and proatherogenic cytokines, without significant differences in body weight, plasma cholesterol, or plasma glucose.
- Live *Bacteroides* treatment decreased predicted microbial LPS biosynthesis genes *LpxA* and *LpxD* and dramatically lowered fecal LPS; heat-killed *Bacteroides* did not decrease fecal LPS, aortic sinus plaque, or plasma LPS compared with controls (reported P=0.92, P=0.74, and P=0.93, respectively).
Methods
- Human study: 30 patients with CAD and 30 controls without CAD with coronary risk factors were recruited at Kobe University Hospital between October 2014 and July 2015; fecal samples underwent 16S rRNA gene sequencing (V3–V4 region), qPCR, PICRUSt functional prediction, and limulus amebocyte lysate assay for LPS.
- Mouse study: 6-week-old female apolipoprotein E-deficient mice on C57BL/6 background were randomized to control, live *Bacteroides*, or heat-killed *Bacteroides* groups; mice were gavaged 5 times per week for 10 weeks and euthanized at 16 weeks for atherosclerosis, immune, gut permeability, and LPS analyses.
- Statistical analysis used R, JMP, and Prism; Shapiro-Wilk test, Student’s t test or Mann-Whitney U test, Fisher exact or χ² test, Spearman correlation, one-way ANOVA, and Benjamini-Hochberg adjustment for multiple comparisons.
Limitations
- The paper states that 16S rRNA sequencing has low phylogenetic power at the species level and poor discriminatory power for some genera, and that the human CAD gut microbial analysis was a single-center study with a relatively small number of patients.
- The paper states that controls without CAD did not all undergo coronary angiography, so subclinical CAD may have been present; the limulus amebocyte lysate assay could not measure LPS immunogenicity or the impact of *Bacteroides* on LPS structure/function; mechanisms of atherosclerosis protection by lower LPS were not completely elucidated; mouse and human dominant microbiota differ; and only *B. vulgatus* and *B. dorei* were tested, so more effective strains may exist.
- Evident from the text: the human findings are cross-sectional and cannot establish causality, and the causal evidence comes from a mouse gavage model rather than a human intervention.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 32 cited sources checked · 0 supported · 0 flagged
- Findingown data
Immunohistochemical staining revealed a marked reduction in macrophage and CD4+ T-cell accumulation in atherosclerotic lesions of mice gavaged with live Bacteroides compared with controls.
“immunohistochemical staining followed by morphometric analysis of atherosclerotic lesions in the aortic sinus revealed a marked reduction in macrophage and CD4 + T-cell accumulation in mice gavaged with live Bacteroides compared with controls (Figure 2C and 2D).”
Quote in the paperSubstantial claim - Findingown data
HT29 cells stimulated with fecal supernatant from live Bacteroides-treated mice had significantly higher ZO-1 mRNA and protein expression than cells stimulated with control supernatant.
“we observed significantly higher expression levels of ZO-1 (mRNA and protein) in HT29 cells stimulated with fecal supernatant from live Bacteroides-treated mice than in cells stimulated with fecal supernatant from control mice (Figure VD and VE in the online-only Data Supplement).”
Quote in the paperSubstantial claim - Findingown data
The abundance of Bacteroides vulgatus and Bacteroides dorei was decreased in patients with coronary artery disease.
“we found that the abundance of Bacteroides vulgatus and Bacteroides dorei was decreased in patients with CAD.”
- Also stated in: § Gut Microbial Profile in Patients With CAD · plain
“patients with CAD showed a relative depletion of B. vulgatus and B. dorei”
Quote in the paperSubstantial claim - Also stated in: § Gut Microbial Profile in Patients With CAD · plain
- Findingown data
mRNA expression of several proatherogenic immune cell markers and chemokines/chemokine receptors was decreased in mice gavaged with live Bacteroides.
“The mRNA expression of several proatherogenic immune cell markers and chemokines/ chemokine receptors was decreased in mice gavaged with live Bacteroides (Figure 2E).”
Quote in the paperSubstantial claim - Findingown data
Mice gavaged with live Bacteroides showed higher mean fluorescence intensity of ZO-1 in the colon.
“reflected in higher mean fluorescence intensity of ZO-1 in the colon (Figure VC in the online-only Data Supplement).”
Quote in the paperSubstantial claim
- Findingown data
Expression of genes related to trimethylamine synthesis (CutC, CutD) did not differ among the groups.
“Although the expression of genes related to TMA synthesis (CutC, CutD) had no difference among the groups”
Quote in the paperNot a substantial claim - Findingown data
The relative abundance of the genus Bacteroides was visibly lower in patients with coronary artery disease compared with controls.
“We found that the relative abundance of the genus Bacteroides was visibly lower in patients with CAD compared with controls (Figure 1G).”
Quote in the paperSubstantial claim - Findingown data
The abundance of B. vulgatus and B. dorei was considerably higher in feces from live Bacteroides-gavaged mice.
“The abundance of B. vulgatus and B. dorei was considerably higher in feces from live Bacteroides-gavaged mice (Figure IIIF in the online-only Data Supplement).”
Quote in the paperSubstantial claim - Findingown data
Expression of genes involved in lipopolysaccharide biosynthesis, especially LpxA and LpxD, was significantly decreased in mice gavaged with live Bacteroides.
“the expression of genes involved in LPS biosynthesis, especially LpxA and LpxD, which are involved in lipid A biosynthesis and constitute the essential acyltransferases of the lipid A structure (Figure 3B), 38,39 was significantly decreased in mice gavaged with live Bacteroides (Figure 3A and 3C, Figure IV in the online-only Data Supplement).”
Quote in the paperSubstantial claim0 of 2 sources checked - Findingown data
The significantly decreased abundance of B. vulgatus and B. dorei in patients with coronary artery disease was confirmed by quantitative polymerase chain reaction.
“We also confirmed the significantly decreased abundance of B. vulgatus and B. dorei in patients with CAD by quantitative polymerase chain reaction (Figure 1J and Table II in the online-only Data Supplement).”
Quote in the paperSubstantial claim - Findingown data
Fecal lipopolysaccharide levels were dramatically lower in mice gavaged with live Bacteroides than in control mice.
“the fecal LPS levels were dramatically lower in mice gavaged with live Bacteroides than in control mice (Figure 3D).”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Findingown data
Mice gavaged with live Bacteroides showed significantly higher mRNA expression of tight junction gene Zo1.
“significantly higher mRNA expression of tight junction gene Zo1 (Figure VB and Table III in the online-only Data Supplement)”
Quote in the paperSubstantial claim - Findingown data
Mice gavaged with live Bacteroides showed lower intestinal permeability to fluorescein isothiocyanate dextran.
“Mice gavaged with live Bacteroides showed lower intestinal permeability to fluorescein isothiocyanate dextran (Figure VA in the online-only Data Supplement)”
Quote in the paperSubstantial claim - Findingown data
The number of CD4+ T cells was lower in live Bacteroides-treated mice.
“the number of CD4 + T cells was also lower in live Bacteroides-treated mice (Figure IIC in the onlineonly Data Supplement).”
Quote in the paperNot a substantial claim - Findingown data
Bacteroides-treated mice had lower plasma levels of proatherogenic cytokines IL-2, IL-4, IL-6, IL-17A, interferon-gamma, and tumor necrosis factor-alpha.
“lower plasma levels of proatherogenic cytokines, such as interleukin (IL)-2, IL-4, IL-6, IL-17A, interferonγ, and tumor necrosis factor-α (Figure 2I).”
Quote in the paperSubstantial claim - Findingown data
Prediction of bacterial gene functions based on 16S rRNA gene sequences using PICRUSt revealed functional diversity among the three groups in accordance with differences in gut microbiota composition.
“the prediction of bacterial gene functions based on 16S rRNA gene sequences using PICRUSt 27 revealed some functional diversity among the 3 groups in accordance with the difference in gut microbiota composition (Figure IIIH in the online-only Data Supplement).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [27] source
Not checked in the free run.
- Findingown data
Bacteroides-treated mice had significantly lower plasma levels of lipopolysaccharide than control mice.
“compared with control mice, Bacteroides-treated mice had significantly lower plasma levels of LPS (Figure 2H)”
Quote in the paperSubstantial claim - Findingown data
Copy number of 16S rDNA per gram feces was significantly increased in mice treated with live Bacteroides compared with control mice.
“Copy number of 16S rDNA per gram feces was significantly increased in mice treated with live Bacteroides compared with control mice”
Quote in the paperNot a substantial claim - Findingown data
16S rRNA gene sequencing of mouse fecal samples revealed changes in gut microbiota composition in response to gavage with live B. vulgatus and B. dorei.
“16S rRNA gene sequencing of mouse fecal samples revealed changes in gut microbiota composition in response to gavage with live B. vulgatus and B. dorei”
Quote in the paperNot a substantial claim - Findingown data
Cytokine mRNA expression in mesenteric lymph nodes tended to be lower in mice treated with live Bacteroides.
“Cytokine mRNA expression in MLNs tended to be lower in mice treated with live Bacteroides (Figure VIG and Table III in the online-only Data Supplement).”
Quote in the paperSubstantial claim - Findingown data
Gut microbial lipopolysaccharide (LPS) biosynthesis is altered after treatment with live Bacteroides.
“Alteration in gut microbial lipopolysaccharide (LPS) biosynthesis after treatment with live Bacteroides”
Quote in the paperSubstantial claim - Findingown data
Expression of LpxM, which yields hexa-acylated lipid A, tended to be higher in the coronary artery disease group.
“the expression of LpxM, which yields hexa-acylated lipid A (a strong TLR4 agonist), tended to be higher in the group with CAD (Figure 4A and 4B).”
Quote in the paperSubstantial claim - Findingown data
Mice gavaged with live Bacteroides had substantially lower mRNA expression of Cd11c, Cd80, and proinflammatory cytokines in the colon.
“Mice gavaged with live Bacteroides had substantially lower mRNA expression of Cd11c, Cd80, and proinflammatory cytokines in the colon.”
Quote in the paperSubstantial claim - Findingown data
ZO-1 expression in the colon was significantly higher in mice treated with live Bacteroides.
“We show for the first time that ZO-1 expression in the colon was significantly higher in mice treated with live Bacteroides”
Quote in the paperSubstantial claim - Findingown data
Bacteroides-gavaged mice had significantly reduced expression of TLR4, MHC class II, and CD80 on CD11c high cells in mesenteric lymph nodes.
“significantly reduced expression of TLR4, major histocompatibility complex class II, and CD80 on CD11c high cells”
- Also stated in: § ORIGINAL RESEARCH ARTICLE · boosted
“We demonstrated that live Bacteroides treatment reduced TLR4 expression and activation and maturation markers, such as major histocompatibility complex class II, CD80, and CD86, on CD11c high dendritic cells in gut-draining MLNs.”
Quote in the paperSubstantial claim - Also stated in: § ORIGINAL RESEARCH ARTICLE · boosted
- Findingown data
Bacteroides-gavaged mice had significantly lower abundance of CD11c high cells in mesenteric lymph nodes.
“Flow-cytometric analysis of MLNs showed that Bacteroides-gavaged mice had significantly lower abundance of CD11c high cells”
Quote in the paperSubstantial claim - Findingown data
Fecal lipopolysaccharide levels in patients with coronary artery disease were significantly higher than in controls.
“fecal LPS levels in patients with CAD were significantly higher than controls (Figure 4C).”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Findingown data
The abundance of genus Bacteroides tended to be negatively correlated with fecal lipopolysaccharide levels (r=-0.227, P=0.0838).
“the abundance of genus Bacteroides tended to be negatively correlated with fecal LPS levels (r=-0.227,P=0.0838).”
Quote in the paperNot a substantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Findingown data
Expression of LpxA and LpxD did not differ between patients with coronary artery disease and controls.
“Although the expression of LpxA and LpxD did not differ between the patients with CAD and controls”
Quote in the paperNot a substantial claim - Findingown data
RAW cells transfected with Tlr4 small-interfering RNA secreted significantly lower levels of proinflammatory cytokines than RAW cells transfected with control small-interfering RNA.
“RAW cells transfected with Tlr4 small-interfering RNA secreted significantly lower levels of proinflammatory cytokines than RAW cells transfected with control small-interfering RNA (Figure VIH in the online-only Data Supplement).”
Quote in the paperSubstantial claim - Findingown data
In RAW cells transfected with control small-interfering RNA, secretion of proinflammatory cytokines IL-1beta, IL-6, and tumor necrosis factor-alpha was markedly lower when stimulated with fecal supernatant from live Bacteroides-treated mice than with control supernatant.
“on transfection with control small-interfering RNA, the secretion of proinflammatory cytokines IL-1β, IL-6, and tumor necrosis factor-α was markedly lower in RAW cells stimulated with fecal supernatant from live Bacteroides-treated mice than in RAW cells treated with fecal supernatant from control mice.”
Quote in the paperSubstantial claim - Findingown data
ZO-1 expression levels in HT29 cells stimulated with fecal supernatant from live Bacteroides-treated mice were significantly higher.
“and significantly higher expression levels of ZO-1 in HT29 cells stimulated with fecal supernatant from live Bacteroides-treated mice”
Quote in the paperSubstantial claim - Findingown data
mRNA expression of Ccr7 was significantly lower in the colon of mice gavaged with Bacteroides.
“the mRNA expression of Ccr7, which is critically important for migration of antigen-presenting cells in the intestinal lamina propria to the mesenteric lymph nodes (MLNs), 44 was significantly lower in the colon of mice gavaged with Bacteroides (Figure VIA and VIB, Table III in the onlineonly Data Supplement).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [44] source
Not checked in the free run.
- Findingown data
We identified the gut bacterial species involved in human CAD.
“we identified the gut bacterial species involved in human CAD”
Quote in the paperSubstantial claim- Rests on an assumption: 16S rRNA sequencing analysis has low phylogenetic power at the species level and poor discriminatory power for some genera.
- Premisecitation
Gut microbiota has a strong relationship with the progression of cardiovascular diseases, including coronary artery disease.
“Increasing evidence has suggested a strong relationship between gut microbiota and the progression of cardiovascular diseases, and we previously reported such a relationship with coronary artery disease (CAD) for the first time.1,2”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
The abundance of Bacteroides is lower in coronary artery disease patients than in non-CAD patients with coronary risk factors or in healthy volunteers.
“our previous study using terminal-restriction fragment length polymorphism analysis confirmed that the abundance of Bacteroides is lower in CAD patients than in non-CAD patients with coronary risk factors or in healthy volunteers.1,2”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationreasoning
The cited findings strongly suggest a relationship between Bacteroides and coronary artery disease.
“Taken together, these findings strongly suggest a relationship between Bacteroides and CAD.”
Quote in the paperSubstantial claim - Premisecitation
Bacteroides abundance is decreased in patients with atherosclerotic ischemic stroke and transient ischemic attack.
“Moreover, Bacteroides abundance was found to be decreased in patients with atherosclerotic ischemic stroke and transient ischemic attack.10”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [10] source
Not checked in the free run.
- Interpretationown data
Endotoxemia was attenuated in live Bacteroides-gavaged mice.
“Thus, endotoxemia was attenuated in live Bacteroidesgavaged mice (Figure 2H).”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Premisecitation
Individuals classified as enterotype 3, characterized by low levels of Bacteroides, have a higher incidence of symptomatic atherosclerosis.
“Individuals classified as enterotype 3, which is characterized by low levels of Bacteroides, 8 have a higher incidence of symptomatic atherosclerosis.1,9”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Gut microbial enzymes producing trimethylamine were enriched in patients with coronary artery disease compared with healthy controls.
“The metagenome-wide association study showed that gut microbial enzymes producing TMA were enriched in patients with CAD compared with healthy controls.5”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] source
Not checked in the free run.
- Premisecitation
B. vulgatus and B. dorei have been implicated to have an anti-inflammatory response.
“These species have been implicated to have an anti-inflammatory response 33”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [33] source
Not checked in the free run.
- Interpretationreasoning
Dampening of systemic innate immune cell activation and Th1-driven inflammation involved in atherosclerosis pathogenesis was caused by live Bacteroides treatment-induced reduction in plasma lipopolysaccharide concentration.
“Taken together, these data suggest that the dampening of systemic innate immunecell activation and Th1-driven inflammation involved in the pathogenesis of atherosclerosis was caused by the live Bacteroides treatment-induced reduction in plasma LPS concentration.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
- Interpretationreasoning
Gut microbiota-induced changes in colon lipopolysaccharide concentrations may directly affect tight junction-mediated paracellular permeability.
“These results suggest that gut microbiota-induced changes in colon LPS concentrations may directly affect tight junction-mediated paracellular permeability.”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Rests on an assumption: The impact of colon lipopolysaccharide concentrations on intestinal permeability has not been fully investigated to date.
- Interpretationown data
The abundance of B. vulgatus and B. dorei has a direct impact on microbial lipopolysaccharide synthesis in the human gut.
“This finding suggests that the abundance of B. vulgatus and B. dorei has a direct impact on microbial LPS synthesis in the human gut.”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Premisecitation
Lipopolysaccharide content per cell varies substantially even within the same strain because bacteria can adapt lipopolysaccharide production according to environmental conditions.
“LPS content per cell is known to vary substantially even within the same strain because bacteria can adapt LPS production according to environmental conditions, 45”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] source
Not checked in the free run.
- Interpretationreasoning
Fecal LPS levels might serve as a novel dysbiosis marker.
“Our findings suggest that fecal LPS levels might serve as a novel dysbiosis marker”
Quote in the paperSubstantial claim- Rests on an assumption: Gut microbial profiles depend on age, sex, local food or lifestyle, and many other factors, making it difficult to define dysbiosis in atherosclerosis.
- Interpretationown data
Colon LPS concentrations produced by gut microbiota contribute to gut barrier strength in vivo and in vitro.
“our study provides the first evidence that colon LPS concentrations produced by gut microbiota contribute to the gut barrier strength in vivo and in vitro”
Quote in the paperSubstantial claim - Interpretationreasoning
Bacteroides treatment may serve as a novel and attractive therapeutic strategy for suppressing inflammatory response in diseases involving gut microbiota-derived LPS and systemic endotoxemia.
“our findings suggest that Bacteroides treatment may serve as a novel and attractive therapeutic strategy for suppressing inflammatory response in such diseases”
Quote in the paperSubstantial claim- Rests on an assumption: The relative abundances of most of the dominant gut microbiota in mice and humans are quite different.
- Interpretationown data
Colonic lipopolysaccharide concentration regulates colon inflammation via LPS/TLR4-dependent signaling.
“Taken together, these findings suggest that colonic LPS concentration regulates colon inflammation via LPS/ TLR4-dependent signaling.”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Interpretationown data
Live B. vulgatus and B. dorei attenuate atherosclerotic lesions by ameliorating endotoxemia.
“Live B. vulgatus and B. dorei attenuate atherosclerotic lesions by ameliorating endotoxemia”
Quote in the paperSubstantial claim
- May combine two claims. 29
- Classified as probably not a substantial claim. 21
- The quote only partly states this claim. 2
May combine two claims.
Findingown dataMice gavaged with Bacteroides exhibited decreased expression of MHC class II and CD86, and increased expression of PD-L1 and PD-L2 on splenic CD11c high dendritic cells.
“mice gavaged with Bacteroides exhibited decreased expression of major histocompatibility complex class II and costimulatory molecule CD86, as well as increased expression of the coinhibitory molecules programmed death ligand-1 and programmed death ligand-2 on splenic CD11c high dendritic cells (Figure IIB in the online-only Data Supplement).”
- Also stated in: § ORIGINAL RESEARCH ARTICLE · plain
“Similar phenotypic changes along with increased expression of PD-L1 and PD-L2 in dendritic cells were observed in the spleen.”
Quote in the paperSubstantial claim- Also stated in: § ORIGINAL RESEARCH ARTICLE · plain
Probably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataGut microbial samples clustered into three clusters at the genus level.
“the samples were clustered into 3 clusters at the genus level”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataMice gavaged with live Bacteroides showed significantly reduced lesion size in the aortic root and en face analysis of thoracoabdominal aortas.
“mice gavaged with live Bacteroides showed significantly reduced lesion size in the aortic root and en face analysis of thoracoabdominal aortas (Figure 2A and 2B)”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataControls without coronary artery disease were significantly more likely to be categorized into cluster 1, whereas few patients with coronary artery disease were categorized into this cluster.
“The controls without CAD were significantly more likely to be categorized into cluster 1, whereas few patients with CAD were categorized into this cluster (Figure 1F).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThere was no significant difference in body weight, plasma cholesterol levels, or plasma glucose levels between live Bacteroides-gavaged mice and controls.
“without significant difference in body weight (Figure 2F), plasma cholesterol levels (Figure 2G), or plasma glucose levels (data not shown).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataEach cluster was characterized by high abundance of a specific genus: Bacteroides in cluster 1, Prevotella in cluster 2, and Faecalibacterium, Ruminococcus, or Bifidobacterium in cluster 3.
“Each cluster was characterized by a high abundance of a specific genus as follows: Bacteroides in cluster 1, Prevotella in cluster 2, and Faecalibacterium, Ruminococcus, or Bifidobacterium in cluster 3 (Figure 1E).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataMice gavaged with live Bacteroides had lower numbers of effector CD44 high CD62Llow CD4+ T cells and a significantly higher proportion of CD4+CD25+Foxp3+ regulatory T cells, with higher levels of intracellular CTLA4.
“Mice gavaged with live Bacteroides had lower numbers of effector CD44 high CD62Llow CD4 + T cells and a significantly higher proportion of CD4 + CD25 + Foxp3 + regulatory T cells, with higher levels of intracellular CTLA4 (Figure IID and IIE in the online-only Data Supplement)”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataPatients with coronary artery disease showed relative depletion of B. vulgatus and B. dorei and enrichment in Faecalibacterium prausnitzii and Prevotella copri.
“patients with CAD showed a relative depletion of B. vulgatus and B. dorei and enrichment in Faecalibacterium prausnitzii and Prevotella copri (Figure 1H).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAlpha diversity, the Bacteroidetes/Firmicutes ratio, and the Gram-positive to Gram-negative strain ratio did not differ significantly between coronary artery disease patients and controls.
“The α diversity, Bacteroidetes/Firmicutes ratio, and Gram-positive to Gramnegative strain ratio did not differ significantly between the 2 groups (Figure 1A and 1C).”
Quote in the paperNot a substantial claimMay combine two claims. The quote only partly states this claim.
Findingown dataB. vulgatus and B. dorei were the two most abundant species within the genus Bacteroides in 16S rRNA gene sequencing analysis and are dominant species of genus Bacteroides in human gut microbiota.
“were the 2 most abundant species within the genus Bacteroides in 16S rRNA gene sequencing analysis (Figure 1I).”
- Also stated in: § DISCUSSION · plain
“B. vulgatus and B. dorei are the dominant species of genus Bacteroides in human gut microbiota.”
Quote in the paperSubstantial claim- Also stated in: § DISCUSSION · plain
May combine two claims.
Findingown dataThe Bacteroidetes/Firmicutes ratio, Gram-positive to Gram-negative strain ratio, and fecal water content did not differ significantly among the 3 groups.
“The Bacteroidetes/Firmicutes ratio, Gram-positive to Gram-negative strain ratio, and fecal water content did not differ significantly among the 3 groups”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe number of CD4+ T cells and several markers on CD4+ T cells did not significantly change in mesenteric lymph nodes of Bacteroides-gavaged mice.
“whereas the number of CD4 + T cells and several markers on CD4 + T cells did not significantly change (Figure VIC and VIF in the online-only Data Supplement).”
Quote in the paperNot a substantial claimThe quote only partly states this claim.
Findingown dataIn patients with coronary artery disease, the abundance of B. vulgatus and B. dorei was significantly negatively correlated with fecal lipopolysaccharide levels (r=-0.541, P=0.002).
“we found that fecal LPS levels were higher in patients with lower abundance of B. vulgatus and B. dorei.”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationTrimethylamine and trimethylamine N-oxide, gut microbiota metabolites of dietary phosphatidylcholine, are associated with cardiovascular disease and with atherosclerosis.
“Trimethylamine (TMA) and TMA N-oxide, which are gut microbiota metabolites of dietary phosphatidylcholine, are known to be associated with cardiovascular disease and with the atherosclerosis process in particular.3,4”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationCoronary artery disease remains the leading cause of morbidity and mortality worldwide despite widespread statin therapy.
“CAD remains the leading cause of morbidity and mortality worldwide, despite the widespread use of statin therapy in the last decade.12”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [12] source
Not checked in the free run.
May combine two claims.
PremisecitationEndotoxemia causes systemic inflammation leading to disruption of innate and adaptive immunity and development of atherosclerosis.
“Endotoxemia is known to cause systemic inflammation leading to the disruption of innate and adaptive immunity and the development of atherosclerosis.[34][35][36]”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [34]
Not checked in the free run.
- cites [35] source
Not checked in the free run.
- cites [36]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationFish consumption drastically increases circulating trimethylamine N-oxide levels.
“a recent clinical trial has shown contradictory results indicating that fish consumption drastically increases circulating TMA N-oxide levels”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [6] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataThe study was approved by the Ethics Committee of Kobe University and registered with the University Hospital Medical Information Network Clinical Trials Registry.
“This study was approved by the Ethics Committee of Kobe University (approval No. 1595) and registered with the University hospital Medical Information Network Clinical Trials Registry (trial registration No. UMIN000015703).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataThe success of heat-killing B. vulgatus and B. dorei was confirmed by absence of growth of plated heat-killed bacteria.
“The success of the heat treatment was confirmed by the absence of growth of plated heat-killed bacteria.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenAll participants provided written informed consent and the study was conducted according to the Declaration of Helsinki.
“All participants provided written informed consent on enrollment, and the study was conducted according to the guidelines of the Declaration of Helsinki.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAll animal experiments were performed according to the Guidelines for Animal Experiments at Kobe University School of Medicine.
“All experiments were performed according to the Guidelines for Animal Experiments in effect at Kobe University School of Medicine (guideline No. P160701).”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
PremisecitationIt remains unclear which specific Bacteroides species are involved and what their exact role is in coronary artery disease.
“However, it remains unclear which specific Bacteroides species are involved and what their exact role is in CAD.11”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11]
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductown dataSix-week-old apolipoprotein E-deficient mice were randomly divided into three treatment groups.
“Six-week-old mice were randomly divided into 3 treatment groups”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductcitationB. vulgatus and B. dorei share similar 16S rRNA sequencing patterns, so they could not be distinguished by the study's methodology.
“Because these 2 species share similar 16S rRNA sequencing patterns, 32 we were not able to distinguish them using our methodology.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [32]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataThe study sample size was calculated to be 30 per group using R software with power 0.9, significance level 0.05, mean difference 6, and SD 7.
“The sample size was calculated using R software (power=0.9,significance level=0.05,mean difference=6, SD=7; n=30 per group.).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationThe genus Bacteroides includes some of the predominant gut bacteria in humans and has an important role in maintaining a healthy gut ecosystem.
“The genus Bacteroides includes some of the predominant gut bacteria in humans and is known to have an important role in maintaining a healthy gut ecosystem.7”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7]
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
PremisecitationLipopolysaccharide stimulates cells through TLR4 and upregulates costimulatory molecules on antigen-presenting cells.
“Because LPS stimulates cells through TLR4 and upregulates costimulatory molecules on antigen-presenting cells, 37”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [37]
Not checked in the free run.
May combine two claims.
Interpretationown dataReplenishment of live B. vulgatus and B. dorei by oral gavage reduced plaque inflammation, attenuating atherosclerotic lesion formation.
“These results suggested that replenishment of live B. vulgatus and B. dorei by oral gavage reduced plaque inflammation, attenuating atherosclerotic lesion formation.”
Quote in the paperSubstantial claim- Rests on an assumption: The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationLipopolysaccharide from Escherichia coli increases intestinal permeability in a TLR4-dependent manner.
“Although LPS from E. coli increases intestinal permeability in a TLR4-dependent manner, 40,41”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [40]
Not checked in the free run.
- cites [41]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductreasoningWe did not perform coronary angiography for all the controls without CAD, so there might have been individuals with subclinical CAD in the control group.
“because we did not perform coronary angiography for all the controls without CAD, there might have been individuals with subclinical CAD in the control group”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductreasoningWe did not fully elucidate the characteristics of gut microbial composition in CAD.
“These limitations imply that we did not fully elucidate the characteristics of gut microbial composition in CAD”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductnone given16S rRNA sequencing analysis helped to seek candidate and translate to animal experiments.
“16S rRNA sequencing analysis helped to seek candidate and translate to animal experiments”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationGut microbiota-derived LPS and systemic endotoxemia are involved in the onset and progression of atherosclerosis and other prevalent disorders such as inflammatory bowel disease, obesity and related metabolic diseases, and nonalcoholic steatohepatitis.
“Given that gut microbiota-derived LPS and systemic endotoxemia are involved in the onset and progression of not only atherosclerosis but also many prevalent disorders, such as inflammatory bowel disease, obesity and related metabolic diseases, and nonalcoholic steatohepatitis, [47][48][49]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [47][48][49]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenThe gut microbial analysis in patients with CAD was a single-center study with a relatively small number of patients.
“the gut microbial analysis in patients with CAD was a single-center study with a relatively small number of patients”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataB. vulgatus and B. dorei have a causal relationship with atherosclerosis, clarified using a mouse model.
“used a mouse model to clarify the causal relationship between B. vulgatus and B. dorei and atherosclerosis”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe lipopolysaccharide compounds penta- and tetraacylated lipid A of B. vulgatus and B. dorei are structurally distinct from the hexa-acylated lipopolysaccharide of Escherichia coli and elicit reduced TLR4 responses.
“the LPS compounds penta-and tetraacylated lipid A of these Bacteroides species are structur-ally distinct from the hexa-acylated LPS of E.scherichia coli and elicit reduced TLR4 responses.33”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [33] source
Not checked in the free run.
May combine two claims.
Interpretationown dataB. vulgatus and B. dorei regulate gut microbial production of lipopolysaccharide and their activity can influence the progression of atherosclerosis in patients with coronary artery disease.
“These results strongly support the idea that B. vulgatus and B. dorei regulate gut microbial production of LPS and that their activity can influence the progression of atherosclerosis in patients with CAD.”
Quote in the paperSubstantial claim- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Rests on an assumption: The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
May combine two claims.
InterpretationcitationAugmentation of tolerogenic dendritic cell phenotype in mesenteric lymph nodes or spleen was suspected to migrate into the blood and was closely associated with attenuated atherosclerotic lesion formation.
“we considered that augmentation of these tolerogenic dendritic cells' phenotype in MLNs or spleen was suspected to migrate into the blood and was closely associated with attenuated atherosclerotic lesion formation as previously reported.42,43,46”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [42]
Not checked in the free run.
- cites [43]
Not checked in the free run.
- cites [46]
Not checked in the free run.
- The authors state this as an assumption: Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
Classified as probably not a substantial claim.
Study design and conductnone givenWe performed gavage only with B. vulgatus and B. dorei.
“we performed gavage only with B. vulgatus and B. dorei”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningB. vulgatus and B. dorei might improve the enteric environment, providing gut bacteria with good living conditions and having a beneficial effect on bacterial lipopolysaccharide production.
“we believe that B. vulgatus and B. dorei might improve the enteric environment, providing gut bacteria with good living conditions and having a beneficial effect on bacterial LPS production.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenWe did not completely elucidate the mechanisms of atherosclerosis protection by lower LPS concentrations in mice.
“we did not completely elucidate the mechanisms of atherosclerosis protection by lower LPS concentrations in mice”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenThe limulus amebocyte lysate assay could not measure LPS immunogenicity and the impact of Bacteroides on the structure and function of LPS.
“it could not measure LPS immunogenicity and the impact of Bacteroides on the structure and function of LPS”
Quote in the paperNot a substantial claim
The authors state this as an assumption.
Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
“it is intriguing to assume that decreased circulating LPS levels after live Bacteroides treatment may reduce the expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4 + T cell accumulation in atherosclerotic plaque.”
The paper relies on this without support.
Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
“we measured fecal LPS levels as an indicator of colon LPS concentrations pro-duced by gut microbiota.”
The paper relies on this without support.
The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
“Bacteroides treatment may serve as a novel and attractive therapeutic strategy for suppressing lipopolysaccharide-induced inflammatory response in CAD.”
The paper relies on this without support.
The hospital diet consumed by participants did not confound the gut microbiome or fecal lipopolysaccharide measurements.
“Fecal samples were collected while participants were hospitalized and thus consuming a hospital diet for >1 day.”
The paper relies on this without support.
The impact of colon lipopolysaccharide concentrations on intestinal permeability has not been fully investigated to date.
“the impact of colon LPS concentrations on intestinal permeability has not been fully investigated to date.”
The paper relies on this without support.
A specific gut microbiota-based target to prevent coronary artery disease has yet to emerge.
“a specific gut microbiota-based target to prevent CAD has yet to emerge.”
The paper relies on this without support.
Gut microbial profiles depend on age, sex, local food or lifestyle, and many other factors, making it difficult to define dysbiosis in atherosclerosis.
“it is difficult to conclude the definition of dysbiosis in atherosclerosis because each gut microbial profile depends on age, sex, local food or lifestyle, and many other factors”
The paper relies on this without support.
16S rRNA sequencing analysis has low phylogenetic power at the species level and poor discriminatory power for some genera.
“It has low phylogenetic power at the species level and poor discriminatory power for some genera”
The paper relies on this without support.
The relative abundances of most of the dominant gut microbiota in mice and humans are quite different.
“the relative abundances of most of the dominant gut microbiota in mice and human are quite different”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Gavage with gram-negative Bacteroides vulgatus and dorei that produce penta- and tetra-acylated lipid A reduced colonic inflammation, endotoxemia, and atherosclerosis in ApoE−/− mice.
“For instance, gavage with the gram-negative Bacteroides (vulgatus and dorei) that produce penta- and tetra-acylated lipid A – in contrast to the hexa-acylated lipid A of e. coli, reduced colonic inflammation, endotoxemia, and atherosclerosis in ApoE−/− mice31.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Two different articles are assigned the same DOI
MinorReferences 31 and 33 give the identical DOI for articles with different titles, journals, and page ranges. At least one DOI is incorrect.
“Variation in microbiome LPS immunogenicity contributes to autoim- munity in humans. Cell. 2016;165:842-853. doi: 10.1002/art.39783”
“Dysbio- sis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol. 2016;68:2646-2661. doi: 10.1002/art.39783”
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · see citing works
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · see citing works
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,617 · see citing works
Naive Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,770 · see citing works
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,587 · see citing works
UCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114 · see citing works
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116 · see citing works
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865 · see citing works
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548 · see citing works
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · see citing works
STAMP: statistical analysis of taxonomic and functional profiles
Parks, D. H., Tyson, G. W., Hugenholtz, P., & Beiko, R. G. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu494 · Cited by 4,200 · see citing works
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,402 · see citing works
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220 · see citing works
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,331 · see citing works
The gut microbiome in atherosclerotic cardiovascular disease
Jie, Z., Xia, H., Zhong, S.-L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., Zhao, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00900-1 · Cited by 1,638 · see citing works
Symptomatic atherosclerosis is associated with an altered gut metagenome
Karlsson, F. H., Fåk, F., Nookaew, I., Tremaroli, V., Fagerberg, B., Petranovic, D., Bäckhed, F., & Nielsen, J. (2012) · Nature Communications · doi:10.1038/ncomms2266 · Cited by 1,371 · see citing works
Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans
Vatanen, T., Kostic, A. D., d’Hennezel, E., Siljander, H., Franzosa, E. A., Yassour, M., Kolde, R., Vlamakis, H., Arthur, T. D., Hämäläinen, A.-M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.007 · Cited by 1,289 · see citing works
Yarza, P., Richter, M., Peplies, J., Euzéby, J. P., Amann, R., SCHLEIFER, K. H., Ludwig, W., Glöckner, F. O., & Rossello-Mora, R. A. (2008) · Systematic and Applied Microbiology · doi:10.1016/j.syapm.2008.07.001 · Cited by 932 · see citing works
Godon, J., Zumstein, E., Dabert, P., Habouzit, F., & Moletta, R. (1997) · Applied and Environmental Microbiology · doi:10.1128/aem.63.7.2802-2813.1997 · Cited by 924 · see citing works
The gut microbiota and obesity: from correlation to causality
Zhao, L. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3089 · Cited by 847 · see citing works
Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W., & Xu, A. (2016) · Circulation · doi:10.1161/circulationaha.115.019645 · Cited by 775 · see citing works
Guo, S., Al–Sadi, R., Said, H. M., & Ma, T. Y. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.10.014 · Cited by 722 · see citing works
Maeda, Y., Kurakawa, T., Umemoto, E., Motooka, D., Ito, Y., Gotoh, K., Hirota, K., Matsushita, M., Furuta, Y., Narazaki, M., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39783 · Cited by 686 · see citing works
Yin, J., Liao, S., He, Y., Wang, S., Xia, G., Liu, F., Zhu, J., You, C., Chen, Q., Zhou, L., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002699 · Cited by 669 · see citing works
Role of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 647 · see citing works
An insider's perspective: Bacteroides as a window into the microbiome
Wexler, A. G., & Goodman, A. L. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.26 · Cited by 624 · see citing works
Mori, H., Maruyama, F., Kato, H., Toyoda, A., Dozono, A., Ohtsubo, Y., Nagata, Y., Fujiyama, A., Tsuda, M., & Kurokawa, K. (2013) · DNA Research · doi:10.1093/dnares/dst052 · Cited by 592 · see citing works
Determination of bacterial number and biomass in the marine environment
Watson, S. W., Novitsky, T. J., Quinby, H. L., & Valois, F. W. (1977) · Applied and Environmental Microbiology · doi:10.1128/aem.33.4.940-946.1977 · Cited by 590 · see citing works
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.15792 · Cited by 468 · see citing works
Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR
Furet, J., Firmesse, O., Gourmelon, M., Bridonneau, C., Tap, J., Mondot, S., Dore, J. M., & Corthier, G. (2009) · FEMS Microbiology Ecology · doi:10.1111/j.1574-6941.2009.00671.x · Cited by 431 · see citing works
Jang, M. H., Sougawa, N., Tanaka, T., Hirata, T., Hiroi, T., Tohya, K., Guo, Z., Umemoto, E., Ebisuno, Y., Yang, B.-G., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.803 · Cited by 430 · see citing works
Guo, S., Nighot, M., Al–Sadi, R., Alhmoud, T., Nighot, P. K., & Ma, T. Y. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402598 · Cited by 422 · see citing works
Cho, C. E., Taesuwan, S., Malysheva, O. V., Bender, E., Tulchinsky, N. F., Yan, J., Sutter, J. L., & Caudill, M. A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600324 · Cited by 405 · see citing works
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341 · see citing works
Emoto, T., Yamashita, T., Sasaki, N., Hirota, Y., Hayashi, T., So, A., Kasahara, K., Yodoi, K., Matsumoto, T., Mizoguchi, T., et al. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.32672 · Cited by 315 · see citing works
Self-citationColonic Microbiota Signatures across Five Northern European Countries
Lay, C., Rigottier‐Gois, L., Holmstrøm, K., Rajilić-Stojanović, M. D., Vaughan, E. E., de Vos, W. M., Collins, M. D., Thiel, R., Namsolleck, P., Blaut, M., et al. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.7.4153-4155.2005 · Cited by 296 · see citing works
TagCleaner: Identification and removal of tag sequences from genomic and metagenomic datasets
Schmieder, R., Lim, Y. W., Rohwer, F. L., & Edwards, R. A. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-341 · Cited by 244 · see citing works
Waidmann, M., Bechtold, O., Frick, J.-S., Lehr, H.-A., Schubert, S., Dobrindt, U., Loeffler, J., Bohn, E., & Autenrieth, I. B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00672-3 · Cited by 234 · see citing works
AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition
Chassaing, B., Koren, O., Carvalho, F. A., Ley, R. E., & Gewirtz, A. T. (2013) · Gut · doi:10.1136/gutjnl-2013-304909 · Cited by 219 · see citing works
Takeda, M., Yamashita, T., Sasaki, N., Nakajima, K., Kita, T., Shinohara, M., Ishida, T., & Hirata, K. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.215459 · Cited by 201 · see citing works
Self-citationGut microbiota lipopolysaccharide accelerates inflamm-aging in mice
Kim, K.-A., Jeong, J.-J., Yoo, S.-Y., & Kim, D.-H. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0625-7 · Cited by 196 · see citing works
The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis
Geng, S., Chen, K., Yuan, R., Peng, L., Maitra, U., Diao, N., Chen, C., Zhang, Y., Hu, Y., Qi, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13436 · Cited by 183 · see citing works
Emoto, T., Yamashita, T., Kobayashi, T., Sasaki, N., Hirota, Y., Hayashi, T., So, A., Kasahara, K., Yodoi, K., Matsumoto, T., et al. (2017) · Heart and Vessels · doi:10.1007/s00380-016-0841-y · Cited by 174 · see citing works
Self-citationSasaki, N., Yamashita, T., Takeda, M., Shinohara, M., Nakajima, K., Tawa, H., Usui, T., & Hirata, K. (2009) · Circulation · doi:10.1161/circulationaha.109.863431 · Cited by 170 · see citing works
Self-citationArdavı́n, C., Amigorena, S., & Sousa, C. R. E. (2004) · Immunity · doi:10.1016/s1074-7613(03)00352-2 · Cited by 148 · see citing works
Bacteroides dorei sp. nov., isolated from human faeces
Bakir, M. A., Sakamoto, M., Kitahara, M., Matsumoto, M., & Benno, Y. (2006) · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY · doi:10.1099/ijs.0.64257-0 · Cited by 95 · see citing works
Williams, A. H., & Raetz, C. R. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705833104 · Cited by 84 · see citing works
Structure and reactivity of LpxD, the <i>N</i> -acyltransferase of lipid A biosynthesis
Buetow, L., Smith, T. K., Dawson, A., Fyffe, S., & Hunter, W. N. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606356104 · Cited by 78 · see citing works
Mizoguchi, T., Kasahara, K., Yamashita, T., Sasaki, N., Yodoi, K., Matsumoto, T., Emoto, T., Hayashi, T., Kitano, N., Yoshida, N., et al. (2017) · Heart and Vessels · doi:10.1007/s00380-017-0949-8 · Cited by 32 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1002/art.39783 · DOI · Paper page
Cited by
Sorted by citations
Role of gut microbiota in type 2 diabetes pathophysiology
Gurung, M., Li, Z., You, H. M., Rodrigues, R. R., Jump, D. Β., Morgun, A., & Shulzhenko, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.051 · Cited by 1,741 · see citing works
Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization
Zuo, T., Zhang, F., Lui, G. C. Y., Yeoh, Y. K., Li, A. Y. L., Zhan, H., Wan, Y., Chung, A. C. K., Cheung, C. P., Chen, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.048 · Cited by 1,537 · see citing works
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review
Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L. R., & Scaldaferri, F. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03374-w · Cited by 1,498 · see citing works
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089 · see citing works
Gut microbiota and cardiovascular disease.
Witkowski, M., Weeks, T. L., & Hazen, S. L. (2020) · Circulation Research · doi:10.1161/circresaha.120.316242 · Cited by 1,051 · see citing works
High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review
Malesza, I. J., Malesza, M., Walkowiak, J., Mussin, N. M., Walkowiak, D., Aringazina, R. A., Bartkowiak-Wieczorek, J., & Mądry, E. (2021) · Cells · doi:10.3390/cells10113164 · Cited by 807 · see citing works
The Gut Microbiota and Unhealthy Aging: Disentangling Cause from Consequence
DeJong, E. N., Surette, M. G., & Bowdish, D. M. E. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.013 · Cited by 370 · see citing works
Ling, Z., Liu, X., Cheng, Y., Yan, X., & Wu, S. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1867054 · Cited by 366 · see citing works
Gut Microbiota and Intestinal Trans-Epithelial Permeability
Allam‐Ndoul, B., Castonguay-Paradis, S., & Veilleux, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176402 · Cited by 356 · see citing works
Lai, H., Lin, T., Chen, T.-W., Kuo, Y.-L., Chang, C., Wu, T.-R., Shu, C.-C., Tsai, Y.-H., Swift, S., & Lu, C. (2021) · Gut · doi:10.1136/gutjnl-2020-322599 · Cited by 333 · see citing works
Bai, X., Wei, H., Liu, W., Coker, O. O., Gou, H., Liu, C., Zhao, L., Li, C., Zhou, Y., Wang, G., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325021 · Cited by 311 · see citing works
Bacteroides utilization for dietary polysaccharides and their beneficial effects on gut health
Cheng, J., Hu, J., Geng, F., & Nie, S. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.04.002 · Cited by 281 · see citing works
Gut microbiota in the pathogenesis and therapeutic approaches of diabetes
Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104821 · Cited by 251 · see citing works
Gut microbiota and metabolic syndrome
Wang, P.-X., Deng, X., Zhang, C., & Yuan, H. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000696 · Cited by 250 · see citing works
Intestinal microbiome and fitness in kidney disease
Meijers, B. K. I., Evenepoel, P., & Anders, H. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0172-1 · Cited by 223 · see citing works
Nesci, A., Carnuccio, C., Ruggieri, V., D’Alessandro, A., Giorgio, A. D., Santoro, L., Gasbarrini, A., Santoliquido, A., & Ponziani, F. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109087 · Cited by 227 · see citing works
Cai, Y., Huang, F., Lao, X., Lu, Y., Gao, X. J., Alolga, R. N., Yin, K., Zhou, X., Wang, Y., Liu, B., et al. (2022) · npj Biofilms and Microbiomes · doi:10.1038/s41522-022-00273-4 · Cited by 178 · see citing works
Rare ginsenosides: A unique perspective of ginseng research
Fan, W., Fan, L., Wang, Z., Mei, Y., Liu, L., Li, L., Yang, L., & Wang, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.003 · Cited by 169 · see citing works
Leonard, M. M., Valitutti, F., Karathia, H., Pujolassos, M., Kenyon, V., Fanelli, B., Troisi, J., Subramanian, P., Camhi, S., Colucci, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020322118 · Cited by 162 · see citing works
Lipopolysaccharide and the gut microbiota: considering structural variation
Mohr, A. E., Crawford, M. S., Jasbi, P., Fessler, S. N., & Sweazea, K. L. (2022) · FEBS Letters · doi:10.1002/1873-3468.14328 · Cited by 161 · see citing works
Lin, T.-L., Shu, C.-C., Chen, Y.-M., Lu, J.-J., Wu, T.-S., Lai, W.-F., Tzeng, C.-M., Lai, H.-C., & Lu, C.-C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00554 · Cited by 143 · see citing works
Qiao, S., Li, B., Wang, K., Sun, S., Liao, M., Liu, C., Zhou, N., Ma, K., Zhang, Y., Chen, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108005 · Cited by 147 · see citing works
Yu, J. S., Youn, G. S., Choi, J., Kim, C., Kim, B., Yang, S., Lee, J., Park, T., Kim, B. K., Kim, Y. B., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.634 · Cited by 143 · see citing works
Yan, J., Pan, Y., Shao, W., Wang, C., Wang, R., He, Y., Zhang, M., Wang, Y., Li, T., Wang, Z., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01390-0 · Cited by 148 · see citing works
Li, A., Ni, W., Zhang, Q., Li, Y., Zhang, X., Wu, H., Du, P., Hou, J., & Zhang, Y. (2019) · Microbiology and Immunology · doi:10.1111/1348-0421.12749 · Cited by 140 · see citing works
Leonard, M. M., Karathia, H., Pujolassos, M., Troisi, J., Valitutti, F., Subramanian, P., Camhi, S. S., Kenyon, V., Colucci, A., Serena, G., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00906-w · Cited by 141 · see citing works
Human microbiome and metabolic health: An overview of systematic reviews
Michels, N., Zouiouich, S., Vanderbauwhede, B., Vanacker, J., Ruiz, B. I. I., & Huybrechts, I. (2022) · Obesity Reviews · doi:10.1111/obr.13409 · Cited by 146 · see citing works
Wang, C., Xiao, Y., Yu, L., Tian, F., Zhao, J., Zhang, H., Chen, W., & Zhai, Q. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.012 · Cited by 139 · see citing works
Reciprocal Interactions between Epigallocatechin-3-gallate (EGCG) and Human Gut Microbiota In Vitro
Liu, Z., de Bruijn, W. J. C., Bruins, M. E., & Vincken, J. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c03587 · Cited by 136 · see citing works
Bacteroides spp. promotes branched-chain amino acid catabolism in brown fat and inhibits obesity
Yoshida, N., Yamashita, T., Osone, T., Hosooka, T., Shinohara, M., Kitahama, S., Sasaki, K., Sasaki, D., Yoneshiro, T., Suzuki, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103342 · Cited by 132 · see citing works
Self-citationCoronary artery disease is associated with an altered gut microbiome composition
Toya, T., Corban, M., Marietta, E. V., Horwath, I. E., Lerman, L. O., Murray, J. A., & Lerman, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227147 · Cited by 131 · see citing works
Gut Microbiome Alterations in COVID-19
Zuo, T., Wu, X., Wen, W., & Lan, P. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2021.09.004 · Cited by 132 · see citing works
Lee, N. Y., Yoon, S. J., Han, D. H., Gupta, H., Youn, G. S., Shin, M. J., Ham, Y. L., Kwak, M. J., Kim, B., Yu, J. S., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1712984 · Cited by 127 · see citing works
Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids
Liu, C., Du, M., Xie, L., Wang, W.-Z., Chen, B., Yun, C., Sun, X., Luo, X., Jiang, Y., Wang, K., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01570-0 · Cited by 127 · see citing works
Multi-omic integration of microbiome data for identifying disease-associated modules
Muller, E., Shiryan, I., & Borenstein, E. (2024) · Nature Communications · doi:10.1038/s41467-024-46888-3 · Cited by 132 · see citing works
Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives
Borse, S., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2020) · Medical Principles and Practice · doi:10.1159/000511002 · Cited by 134 · see citing works
Altered intestinal microbiome and metabolome correspond to the clinical outcome of sepsis
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04412-x · Cited by 117 · see citing works
Daily, J. W., & Park, S. (2022) · Cells · doi:10.3390/cells11030338 · Cited by 108 · see citing works
Gut microbiota impacts bone via Bacteroides vulgatus-valeric acid-related pathways
Lin, X., Xiao, H.-M., Liu, H.-M., Lv, W.-Q., Greenbaum, J., Gong, R., Zhang, Q., Chen, Y.-C., Peng, C., Xu, X.-J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42005-y · Cited by 101 · see citing works
Gut Microbiota and Atherosclerosis—Focusing on the Plaque Stability
Shen, X., Li, L., Sun, Z., Zang, G., Zhang, L., Shao, C., & Wang, Z. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.668532 · Cited by 99 · see citing works
Kynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?
Kozieł, K., & Urbańska, E. M. (2023) · Cells · doi:10.3390/cells12030460 · Cited by 101 · see citing works
Tsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P., Chen, H., Huang, M., Lin, C.-H., & Tsai, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814770 · Cited by 92 · see citing works
The microbiome-driven impact of western diet in the development of noncommunicable chronic disorders
Severino, A., Tohumcu, E., Tamai, L., D’Argenio, P., Porcari, S., Rondinella, D., Venturini, I., Maida, M. F., Gasbarrini, A., Cammarota, G., et al. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101923 · Cited by 97 · see citing works
Xu, M., Lan, R., Qiao, L., Lin, X., Hu, D., Zhang, S., Yang, H. J., Zhou, J., Ren, Z., Li, X., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02517-22 · Cited by 85 · see citing works
Changes of gut microbiota reflect the severity of major depressive disorder: a cross sectional study
Hu, X., Li, Y., Wu, J., Zhang, H., Huang, Y., Tan, X., Wen, L., Zhou, X., Xie, P., Olasunkanmi, O. I., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02436-z · Cited by 92 · see citing works
A systematic review on gut microbiota in type 2 diabetes mellitus
Chong, S., Lin, M., Chong, D., Jensen, S. O., & Lau, N. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1486793 · Cited by 96 · see citing works
Kim, S., Lee, J., Shin, S. G., Kim, J. K., Silwal, P., Kim, Y. J., Shin, N., Kim, P. S., Won, M., Lee, S., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1847460 · Cited by 80 · see citing works
Farsi, Y., Tahvildari, A., Arbabi, M., Vazife, F., Sechi, L. A., Bonjar, A. H. S., Jamshidi, P. K., Nasiri, M. J., & Mirsaeidi, M. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.804644 · Cited by 78 · see citing works
Anhê, F. F., Zlitni, S., Zhang, S., Choi, B. S.-Y., Chen, C. Y., Foley, K. P., Barra, N. G., Surette, M. G., Biertho, L. D., Richard, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-328185 · Cited by 75 · see citing works
Martemucci, G., Fracchiolla, G., Muraglia, M., Tardugno, R., Dibenedetto, R. S., & D‘Alessandro, A. G. (2023) · Antioxidants · doi:10.3390/antiox12122091 · Cited by 81 · see citing works
Van den Abbeele, P., Verstrepen, L., Ghyselinck, J., Albers, R., Marzorati, M., & Mercenier, A. (2020) · Nutrients · doi:10.3390/nu12071917 · Cited by 73 · see citing works
The gut microbiota and aging: interactions, implications, and interventions
Gyriki, D., Nikolaidis, C. G., Bezirtzoglou, E., Voidarou, C. C., Stavropoulou, E., & Tsigalou, C. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1452917 · Cited by 75 · see citing works
Yoshida, N., Yamashita, T., Kishino, S., Watanabe, H., Sasaki, K., Sasaki, D., Tabata, T., Sugiyama, Y., Kitamura, N., Saito, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69983-z · Cited by 71 · see citing works
Self-citationShort-chain fatty acids: Important components of the gut-brain axis against AD
Huang, Y., Wang, Y. F., Miao, J., Zheng, R. F., & Li, J. Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116601 · Cited by 70 · see citing works
Luo, D., Zhao, W.-B., Lin, Z., Wu, J., Lin, H., Li, Y., Song, J., Zhang, J., & Peng, H. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.579386 · Cited by 70 · see citing works
Kim, E. S., Yoon, B. H., Lee, S. M., CHOI, M. H., Kim, E. H., Lee, B.-W., Kim, S., Pack, C., Sung, Y. H., Baek, I., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00728-w · Cited by 67 · see citing works
Flavonifractor plautii Protects Against Elevated Arterial Stiffness
Luo, S., Zhao, Y., Zhu, S., Liu, L., Cheng, K., Ye, B., Han, Y., Fan, J., & Xia, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.321975 · Cited by 68 · see citing works
Gut Microbiota-Associated Activation of TLR5 Induces Apolipoprotein A1 Production in the Liver
Yiu, J. H. C., Chan, K.-S., Cheung, J., Li, J., Liu, Y., Wang, Y., Fung, W. W. L., Cai, J., Cheung, S. W. M., Dorweiler, B., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317362 · Cited by 67 · see citing works
Zhang, K., Qin, X., Qiu, J., Sun, T. H., Qu, K., Din, A. U., Yan, W., Li, T., Chen, Y., Gu, W., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.09.007 · Cited by 67 · see citing works
Xiao, C., Wang, J., Su, C., Miao, Z., Tang, J., Ouyang, Y., Yan, Y., Jiang, Z., Fu, Y., Shuai, M., et al. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac178 · Cited by 67 · see citing works
Wei, J., Zheng, Z., Hou, X., Jia, F., Yuan, Y., Yuan, F., He, F., Hu, L., & Zhao, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116866 · Cited by 65 · see citing works
Gu, S., Zaidi, S., Hassan, M. I., Mohammad, T., Malta, T. M., Noushmehr, H., Nguyen, B., Crandall, K. A., Srivastav, J., Obias, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.023 · Cited by 63 · see citing works
Forlano, R., Martínez-Gili, L., Takis, P. G., Blanco, J. M., Liu, T., Triantafyllou, E., Skinner, C., Loomba, R. S., Thursz, M. R., Marchesi, J. R., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2304157 · Cited by 65 · see citing works
Jin, S., Chen, P., Yang, J., Li, D., Liu, X., Zhang, Y., Xia, Q., Li, Y., Chen, G., Li, Y., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2309683 · Cited by 65 · see citing works
Koopen, A. M., Almeida, E. L., Attaye, I., Witjes, J. J., Rampanelli, E., Majait, S., Kemper, M., Levels, J. H. M., Schimmel, A. W. M., Herrema, H., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.662159 · Cited by 64 · see citing works
Tousoulis, D., Guzik, T. J., Padró, T., Duncker, D. J., Luca, G. D., Eringa, E. C., Vavlukis, M., Antonopoulos, A. S., Katsimichas, T., Cenko, E., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac057 · Cited by 65 · see citing works
Dai, H., Hou, T., Wang, Q., Hou, Y., Wang, T., Zheng, J., Lin, H., Zhao, Z., Li, M., Wang, S., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad171 · Cited by 64 · see citing works
Zhang, Y., Xu, J., Wang, X., Ren, X., & Liu, Y. (2019) · BMC Genomics · doi:10.1186/s12864-019-6251-7 · Cited by 63 · see citing works
Effect of Gut Microbiota on Blood Cholesterol: A Review on Mechanisms
Deng, C., Pan, J., Zhu, H., & Chen, Z. (2023) · Foods · doi:10.3390/foods12234308 · Cited by 62 · see citing works
Gut microbial composition in patients with atrial fibrillation: effects of diet and drugs
Tabata, T., Yamashita, T., Hosomi, K., Park, J., Hayashi, T., Yoshida, N., Saito, Y., Fukuzawa, K., Konishi, K., Murakami, H., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01669-y · Cited by 63 · see citing works
Self-citationZhang, Y., Zhang, P., Shang, X., Lu, Y., & Li, Y. (2020) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2020.108877 · Cited by 61 · see citing works
Autoimmunity and COVID-19 – The microbiotal connection
Katz-Agranov, N. S., & Zandman‐Goddard, G. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102865 · Cited by 60 · see citing works
The emerging role of gut microbial metabolism on cardiovascular disease
Kasahara, K., & Rey, F. E. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.09.007 · Cited by 58 · see citing works
Sequence meets function—microbiota and cardiovascular disease
Kim, M., Huda, M. N., & Bennett, B. J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab030 · Cited by 59 · see citing works
Zhu, J., & He, L. (2024) · Microorganisms · doi:10.3390/microorganisms12040642 · Cited by 58 · see citing works
Rodriguez, R. M., Hernandez, B. Y., Menor, M., Deng, Y., & Khadka, V. S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.003 · Cited by 57 · see citing works
Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis
Choroszy, M., Litwinowicz, K., Bednarz, R., Roleder, T., Lerman, A., Toya, T., Kamiński, K. A., Sawicka, E., Niemira, M., & Sobieszczańska, B. (2022) · Metabolites · doi:10.3390/metabo12121165 · Cited by 56 · see citing works
Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases
Xu, J., & Yang, Y. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1936379 · Cited by 56 · see citing works
Vulnerable Atherosclerotic Plaque: Is There a Molecular Signature?
Chiorescu, R. M., Mocan, M., Inceu, A.-I., Buda, A. P., Blendea, D. C., & Vlaicu, S. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113638 · Cited by 59 · see citing works
The gut microbiota–bile acid–TGR5 axis orchestrates platelet activation and atherothrombosis
Qi, Z., Zhang, W., Zhang, P., Qu, Y., Zhong, H., Zhou, L., Zhou, W., Yang, W., Xu, H., Zhao, X., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00637-x · Cited by 55 · see citing works
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease
Hage, R. E., Al-Arawe, N., & Hinterseher, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032399 · Cited by 55 · see citing works
Altered gut microbiota of obesity subjects promotes colorectal carcinogenesis in mice
Kang, X., Ng, S.-K., Liu, C., Lin, Y., Zhou, Y., Kwong, T. N. Y., Ni, Y., Lam, T. Y. T., Wu, W. K. K., Wei, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104670 · Cited by 56 · see citing works
Pan, L., Ren, Z., Yang, J., Li, B., Huang, Y., Song, D.-X., Li, X., Xu, J., Bhatia, M., Zou, D., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.002 · Cited by 53 · see citing works
Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H., Jiang, Z., Yang, Y., Wu, T., Zheng, Y., Ma, Y., & Xie, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01464-y · Cited by 54 · see citing works
Chandrarathna, H. P. S. U., Liyanage, T. D., Edirisinghe, S. L., Dananjaya, S. H. S., Jayathilaka, E. H. T. T., Nikapitiya, C., Oh, C., Kang, D.-H., & Zoysa, M. D. (2020) · Marine Drugs · doi:10.3390/md18030175 · Cited by 53 · see citing works
Huang, K., Liu, C., Peng, M., Su, Q., Liu, R.-M., Guo, Z., Chen, S., Li, Z., & Chang, G. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019820 · Cited by 53 · see citing works
Yntema, T., Koonen, D. P. Y., & Kuipers, F. (2023) · Nutrients · doi:10.3390/nu15081850 · Cited by 55 · see citing works
Choi, K. J., Yoon, M. Y., Kim, J.-E., & Yoon, S. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-41160-y · Cited by 51 · see citing works
Jiangu granule ameliorated OVX rats bone loss by modulating gut microbiota-SCFAs-Treg/Th17 axis
Sun, P., Zhang, C., Huang, Y., Yang, J., Zhou, F., Zeng, J., & Lin, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112975 · Cited by 50 · see citing works
The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling
Osorio, C. P., Kanukuntla, T., Diaz, E. L., Jafri, N., Cummings, M., & Sfera, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00143 · Cited by 49 · see citing works
Alterations of Gut Microbiome in Tibetan Patients With Coronary Heart Disease
Liu, F., Fan, C., Zhang, L., Li, Y., Hou, H., Ma, Y., Fan, J., Tan, Y., Wu, T., Jia, S., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00373 · Cited by 50 · see citing works
Fernández, J., de la Fuente, V. G., García, M. T. F., Sánchez, J. G., Redondo, B. I., Villar, C. J., & Lombó, F. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01205-x · Cited by 49 · see citing works
Effects of Sevoflurane Inhalation Anesthesia on the Intestinal Microbiome in Mice
Han, C., Zhang, Z., Guo, N., Li, X., Yang, M., Peng, Y., Ma, X., Yu, K., & Wang, C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.633527 · Cited by 49 · see citing works
Alisma orientalis Beverage Treats Atherosclerosis by Regulating Gut Microbiota in ApoE-/- Mice
Zhu, B., Zhai, Y., Ji, M., Wei, Y., Wu, J., Xue, W., Tao, W. W., & Wu, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.570555 · Cited by 48 · see citing works
Sheng, S.-F., Yan, S., Chen, J.-F., Zhang, Y.-H., Wang, Y.-X., Qin, Q., Li, W., Li, T.-T., Huang, M., Ding, S.-Y., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.946757 · Cited by 41 · see citing works
Forlano, R., Mullish, B. H., Roberts, L. A., Thursz, M. R., & Manousou, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020662 · Cited by 48 · see citing works
New insights into lipopolysaccharide inactivation mechanisms in sepsis
Pérez-Hernández, E. G., Delgado-Coello, B., Luna-Reyes, I., & Mas-Oliva, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111890 · Cited by 56 · see citing works
Chattopadhyay, I., & Shankar, E. M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.590874 · Cited by 46 · see citing works
Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia: probiotics increased
Yang, H.-T., Xiu, W., Liu, J., Yang, Y., Hou, X., Zheng, Y., Wu, T., Wu, C.-X., & Xie, X. (2021) · Bioengineered · doi:10.1080/21655979.2021.1976897 · Cited by 47 · see citing works
Aloo, S. O., & Oh, D. (2022) · Antioxidants · doi:10.3390/antiox11020333 · Cited by 46 · see citing works
- Authors
- Yoshida, N., Emoto, T., Yamashita, T., Watanabe, H., Hayashi, T., Tabata, T., Hoshi, N., Hatano, N., Ozawa, G., Sasaki, N., Mizoguchi, T., Amin, H. Z., Hirota, Y., Ogawa, W., Yamada, T., & Hirata, K.-I.
- Affiliations
- Kobe University (JP)
- Tokyo Institute of Technology (JP)
- Technosuruga Laboratory Co., Ltd. (Japan) (JP)
- University of Indonesia (ID)
- Corresponding author
- Yoshida, Naofumi
- Emoto, Takuo
- ORCID
- Venue
- Circulation
- Published
- 2018-11-27
- Volume
- 138
- Issue
- 22
- Pages
- 2486-2498
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2886282415
- Cited by
- 619
- References
- 50
- Citations by year
- 2026: 52 · 2025: 105 · 2024: 112 · 2023: 113 · 2022: 101 · 2021: 75 · 2020: 47 · 2019: 13 · 2018: 1
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Kobe University Repository Kernel (Kobe University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (16H06279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- Bacteroides vulgatus, Bacteroides dorei, gut microbiota, atherosclerosis, coronary artery disease, lipopolysaccharide, endotoxemia, pro-inflammatory response, fecal microbiota transplantation, gut-heart axis
- MeSH terms
- Gastrointestinal Microbiome, Aged, Animals, Bacteroides, Feces, Female, Humans, Intestines, Lipopolysaccharides, Male, Mice, Inbred C57BL, Middle Aged, Risk Factors, RNA, Ribosomal, 16S, Sequence Analysis, RNA, Mice, Knockout, Immunity, Mucosal, Tight Junctions, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review